Literature DB >> 34838194

Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study.

Hongmei Zeng1, Xianhui Ran1, Lan An1, Rongshou Zheng1, Siwei Zhang1, John S Ji2, Yawei Zhang1, Wanqing Chen1, Wenqiang Wei1, Jie He3.   

Abstract

BACKGROUND: Stage information is crucial for cancer care and essential to improve polices for cancer control. However, the distribution of stage at diagnosis for common cancers in China is not well known. We aimed to identify the distribution and factors associated with stage at diagnosis for five major cancers in China.
METHODS: In this multicentre, hospital-based, observational study, we included 23 hospitals in 12 provinces from China. We focused on cancers of the lung, stomach, oesophagus, colorectum, and female breast, and using electronic medical records at the individual level from the local hospitals, and cancer registration records from population-based cancer registries, identified diagnoses made between Jan 1, 2016, and Dec 31, 2017. We collected information on sociodemographic characteristics, lifestyle factors, insurance types, and stage at diagnosis. We analysed the prevalence of late-stage (stages III-IV) cancer cases overall, by sex, and by geographical region. We used logistic regression to identify the factors that were associated with late stage at diagnosis. We further compared these estimates with data from the USA using the Surveillance, Epidemiology, and End Results database.
FINDINGS: We included 52 103 eligible patients. Among 41 671 patients with known stage at diagnosis, 22 009 (52·8%) were diagnosed with late-stage cancer. The proportion of late-stage cases was higher in men and boys than in women and girls (14 084 [64·1%] of 21 973 vs 7925 [40·2%] of 19 698 patients; diagnosed at stages III-IV; adjusted odds ratio [OR] 1·3, 95% CI 1·2-1·5). There is a persistent diagnostic disparity between rural and urban areas (adjusted OR 1·2, 1·1-1·4). Patients with the new rural cooperative medical scheme insurance had a significantly higher risk of late-stage diagnosis compared with patients with urban insurance (adjusted OR 1·4, 1·1-1·9). By specific cancer type, sex and rural-urban disparities were the largest in lung cancer. Compared with the USA, our study patients had a higher percentage of stage II-IV breast cancer (72·4% in China vs 48·8% in the USA), lung cancer (82·7% in China vs 74·7% in the USA), and colorectal cancer (84·8% in China vs 75·9% in the USA).
INTERPRETATION: The disparities of cancer diagnosis within China, and between China and the USA, indicate an urgent need for early detection of cancer in China. FUNDING: National Key R&D Programme of China, Major State Basic Innovation Programme of the Chinese Academy of Medical Sciences, and National Natural Science Fund.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34838194     DOI: 10.1016/S2468-2667(21)00157-2

Source DB:  PubMed          Journal:  Lancet Public Health


  7 in total

1.  Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.

Authors:  Pinghui Xia; Pan Li; Simeng Wu; Yiqing Wang; Peng Ye; Chong Zhang; Jian Hu; Biniam Kidane; Savvas Lampridis; Jeffrey B Velotta; Connor J Wakefield; Linhai Zhu; Luming Wang
Journal:  Ann Transl Med       Date:  2022-09

2.  The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.

Authors:  Yun-Song Yang; Yi-Xing Ren; Cheng-Lin Liu; Shuang Hao; Xiao-En Xu; Xi Jin; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2022-03-25       Impact factor: 4.872

3.  National Cancer Data Linkage Platform of China: Design, Methods, and Application.

Authors:  Hongmei Zeng; Yunning Liu; Lijun Wang; Peng Yin; Baohua Wang; Ruiying Fu; Xianhui Ran; Rongshou Zheng; Siwei Zhang; Jiangmei Liu; Jinling You; Kexin Sun; Shaoming Wang; Li Li; Ru Chen; Wenqiang Wei; Maigeng Zhou; Jing Wu; Jie He
Journal:  China CDC Wkly       Date:  2022-04-01

4.  Molecular Features in Lymphatic Metastases Reflect the Metastasis Mechanism of Lymph Nodes With Non-Small-Cell Lung Cancers.

Authors:  Nannan Guo; Yuanyuan Chen; Zhongying Jing; Siyao Liu; Junyan Su; Ruilin Li; Xiaohong Duan; Zhigong Chen; Ping Chen; Rongjiang Yin; Shaojun Li; Jian Tang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-18

Review 5.  Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives.

Authors:  Yu Xian Lim; Zi Lin Lim; Peh Joo Ho; Jingmei Li
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

6.  Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China.

Authors:  Siyi He; He Li; Maomao Cao; Dianqin Sun; Fan Yang; Xinxin Yan; Shaoli Zhang; Yutong He; Lingbin Du; Xibin Sun; Ning Wang; Min Zhang; Kuangrong Wei; Lin Lei; Changfa Xia; Ji Peng; Wanqing Chen
Journal:  Transl Lung Cancer Res       Date:  2022-08

7.  Clinicopathological and surgical comparisons of differentiated thyroid cancer between China and the USA: A multicentered hospital-based study.

Authors:  Juan Zhu; Kexin Sun; Jian Wang; Yutong He; Daojuan Li; Shuzheng Liu; Yunchao Huang; Min Zhang; Bingbing Song; Xianzhen Liao; He Liang; Qian Zhang; Mumu Shi; Lanwei Guo; Yongchun Zhou; Yanping Lin; Yanni Lu; Jiyu Tuo; Yafen Xia; Huixin Sun; Haifan Xiao; Yong Ji; Ci Yan; Jinwan Qiao; Hongmei Zeng; Rongshou Zheng; Siwei Zhang; Shaoyan Liu; Sheng Chang; Wenqiang Wei
Journal:  Front Public Health       Date:  2022-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.